IS7671A - Ónæmisvaka samsetningar - Google Patents

Ónæmisvaka samsetningar

Info

Publication number
IS7671A
IS7671A IS7671A IS7671A IS7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A IS 7671 A IS7671 A IS 7671A
Authority
IS
Iceland
Prior art keywords
carbohydrate
parenteral
antigen
sublimation
administration
Prior art date
Application number
IS7671A
Other languages
English (en)
Inventor
Vande Velde Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of IS7671A publication Critical patent/IS7671A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IS7671A 2002-08-13 2005-01-27 Ónæmisvaka samsetningar IS7671A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218821.7A GB0218821D0 (en) 2002-08-13 2002-08-13 Novel compositions
PCT/EP2003/009010 WO2004016241A1 (en) 2002-08-13 2003-08-12 Antigenic compositions

Publications (1)

Publication Number Publication Date
IS7671A true IS7671A (is) 2005-01-27

Family

ID=9942239

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7671A IS7671A (is) 2002-08-13 2005-01-27 Ónæmisvaka samsetningar

Country Status (19)

Country Link
US (1) US20060051372A1 (is)
EP (1) EP1528914B1 (is)
JP (1) JP2006500358A (is)
KR (1) KR20050056965A (is)
CN (1) CN1674867A (is)
AT (1) ATE409459T1 (is)
AU (1) AU2003255440A1 (is)
BR (1) BR0313337A (is)
CA (1) CA2494002A1 (is)
DE (1) DE60323842D1 (is)
GB (1) GB0218821D0 (is)
IL (1) IL166526A0 (is)
IS (1) IS7671A (is)
MX (1) MXPA05001728A (is)
NO (1) NO20050543L (is)
PL (1) PL375590A1 (is)
RU (1) RU2005102589A (is)
WO (1) WO2004016241A1 (is)
ZA (1) ZA200500833B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
BRPI0417264A (pt) * 2003-12-19 2007-03-06 Alk Abello As processos para a preparação de uma batelada de um ingrediente farmacêutico ativo, um recipiente compreendendo criogránulos de um produto alérgeno, e um criogránulo de um produto alérgeno
EP1722819B1 (en) * 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
EP2068834A2 (en) * 2006-09-08 2009-06-17 Becton, Dickinson & Company Stable powder formulations of aluma-dsorbed vaccines
JP2008096503A (ja) * 2006-10-06 2008-04-24 Toshiba Corp 粉末状感光性組成物の製造方法、感光性組成物およびこの感光性組成物から形成された光記録媒体
TW200911304A (en) * 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
DK2200642T3 (da) * 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
EA030733B1 (ru) * 2013-12-19 2018-09-28 Янссен Вэксинс Энд Превеншн Б.В. Жидкая композиция для сохранения виросом и способ сохранения виросом
US20180028627A1 (en) * 2015-02-26 2018-02-01 Bioventures, Llc Treatment vaccine for prostate cancer
CA3031170A1 (en) * 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
MX2021000548A (es) * 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacáridos en seco.
CN117100707A (zh) * 2023-10-19 2023-11-24 江苏瑞科生物技术股份有限公司 一种针对hpv免疫原性蛋白的冻干保护剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
ATE74523T1 (de) * 1984-12-07 1992-04-15 Faruk Hadziselimovic Praeparat zur intramuskulaeren injektion von medikamenten, vitaminen oder impfstoffen.
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6238888B1 (en) * 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations

Also Published As

Publication number Publication date
EP1528914B1 (en) 2008-10-01
DE60323842D1 (de) 2008-11-13
ZA200500833B (en) 2006-08-30
EP1528914A1 (en) 2005-05-11
ATE409459T1 (de) 2008-10-15
AU2003255440A1 (en) 2004-03-03
JP2006500358A (ja) 2006-01-05
PL375590A1 (en) 2005-11-28
BR0313337A (pt) 2005-06-14
CN1674867A (zh) 2005-09-28
RU2005102589A (ru) 2005-10-10
CA2494002A1 (en) 2004-02-26
US20060051372A1 (en) 2006-03-09
GB0218821D0 (en) 2002-09-18
IL166526A0 (en) 2006-01-15
WO2004016241A1 (en) 2004-02-26
NO20050543L (no) 2005-03-11
KR20050056965A (ko) 2005-06-16
MXPA05001728A (es) 2005-05-27

Similar Documents

Publication Publication Date Title
IS7671A (is) Ónæmisvaka samsetningar
EP2709657B1 (en) Thermostable vaccine compositions and methods of preparing same
RU2655627C2 (ru) Вакцинная композиция
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
MXPA03001392A (es) Vacuna de dosis solida oral.
HRP20160276T1 (hr) Pripravci za imuniziranje protiv bakterije staphylococcus aureus
WO2010146598A2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
Gerdts et al. Carrier molecules for use in veterinary vaccines
KR20050084575A (ko) 백신의 개선 또는 백신에 관한 개선
MY148141A (en) Vaccine
Isibasi et al. Active protection of mice against Salmonella typhi by immunization with strain-specific porins
WO2009108689A1 (en) Sugar glassified virus like particles (vlps)
US20040047882A1 (en) Adjuvant for vaccines
JP2013515015A5 (is)
RU2014151424A (ru) Термостабильные составы вакцины
KR20180041237A (ko) Vlp 안정화된 백신 조성물
KR20180043352A (ko) 다가 vlp 접합체
WO2018231706A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR101867428B1 (ko) 경구 백신 투여용의 개선된 항원보강제 시스템
WO2015050178A1 (ja) 鼻粘膜ワクチン組成物
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
CN101296705A (zh) 固体疫苗制剂
KR20200053644A (ko) 보강제 제형 및 방법
KR100586804B1 (ko) 모노포스포릴 지질 에이를 함유하는 보조제 및 백신 조성물
KR20210068429A (ko) 점막 애주번트